Background:Vaccine effectiveness studies have not differentiated the effect of the delta(B.1.617.2)variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections.We aimed t...Background:Vaccine effectiveness studies have not differentiated the effect of the delta(B.1.617.2)variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections.We aimed to evaluate overall and variant-specific effectiveness of BNT162b2(tozinameran,Pfizer-BioNTech)against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.展开更多
Background:Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019(Covid-19)after receiving two doses of the BNT162b2 messenger RNA vaccine(Pfizer-BioNTech)by May 31,2021.After ear...Background:Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019(Covid-19)after receiving two doses of the BNT162b2 messenger RNA vaccine(Pfizer-BioNTech)by May 31,2021.After early reports of myocarditis during adverse events monitoring,the Israeli Ministry of Health initiated active surveillance.展开更多
Dear editor,Myocarditis is a known complication of vaccines for COVID-19,particularly mRNA vaccines.While it is rare,the exact incidence of vaccine-associated myocarditis is unknown.Proponents of personal choice in va...Dear editor,Myocarditis is a known complication of vaccines for COVID-19,particularly mRNA vaccines.While it is rare,the exact incidence of vaccine-associated myocarditis is unknown.Proponents of personal choice in vaccination decisions often cite the risk of myocarditis as a reason one might choose not to receive the COVID-19 vaccination.Herein,we describe a case of focal myocarditis associated with the Pfizer-BioNTech COVID-19 vaccine and review the literature on the incidence and risk of COVID-19 vaccine-associated myocarditis.展开更多
欧洲药品管理局(EMA)近期发布上市许可持有人(Pfizer Europe MA EEIG)就克唑替尼(crizotinib,商品名:赛可瑞/XALKORI)儿童用药患者视觉异常风险的致医生函(DHPC),警示克唑替尼可造成严重的视觉丧失,儿童患者使用克唑替尼需监测视觉情况...欧洲药品管理局(EMA)近期发布上市许可持有人(Pfizer Europe MA EEIG)就克唑替尼(crizotinib,商品名:赛可瑞/XALKORI)儿童用药患者视觉异常风险的致医生函(DHPC),警示克唑替尼可造成严重的视觉丧失,儿童患者使用克唑替尼需监测视觉情况。主要内容如下:概要视觉异常是克唑替尼的已知风险。在克唑替尼临床试验中。展开更多
Background:Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment,we studied mixed priming schedules incorporating an adenoviral-vectored vaccine(Ch...Background:Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment,we studied mixed priming schedules incorporating an adenoviral-vectored vaccine(ChAdOx1 nCoV-19[ChAd],AstraZeneca),two mRNA vaccines(BNT162b2[BNT],Pfizer-BioNTech,and mRNA-1273[m1273],Moderna)and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant(NVX-CoV2373[NVX],Novavax).展开更多
Background:The emergence of the B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine(Pfizer-BioNTech)led to a resurgence of coronav...Background:The emergence of the B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine(Pfizer-BioNTech)led to a resurgence of coronavirus disease 2019(Covid-19)cases in populations that had been vaccinated early.On July 30,2021,the Israeli Ministry of Health approved the use of a third dose of BNT162b2(booster)to cope with this resurgence.Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed.Methods:We obtained data for all members of Clalit Health Services who were 50 years of age or older at the start of the study and had received two doses of BNT162b2 at least 5 months earlier.The mortality due to Covid-19 among participants who received the booster during the study period(booster group)was compared with that among participants who did not receive the booster(nonbooster group).A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association of booster status with death due to Covid-19,with adjustment for sociodemographic factors and coexisting conditions.展开更多
1.聚合物聚丙烯酰胺是最常用的 EOR聚合物,它们比较便宜并能在淡水中产生较高的粘度。目前国外常用的聚丙烯酰胺产品有 DowPusher500、700、1000,Cyanatrol 920、930、940、960,Bet2 Hi Vis 等。生物聚合物是另一类 EOR 聚合物。Pfizer...1.聚合物聚丙烯酰胺是最常用的 EOR聚合物,它们比较便宜并能在淡水中产生较高的粘度。目前国外常用的聚丙烯酰胺产品有 DowPusher500、700、1000,Cyanatrol 920、930、940、960,Bet2 Hi Vis 等。生物聚合物是另一类 EOR 聚合物。Pfizer 公司的 Flocon 4800、展开更多
文摘Background:Vaccine effectiveness studies have not differentiated the effect of the delta(B.1.617.2)variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections.We aimed to evaluate overall and variant-specific effectiveness of BNT162b2(tozinameran,Pfizer-BioNTech)against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.
文摘Background:Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019(Covid-19)after receiving two doses of the BNT162b2 messenger RNA vaccine(Pfizer-BioNTech)by May 31,2021.After early reports of myocarditis during adverse events monitoring,the Israeli Ministry of Health initiated active surveillance.
文摘Dear editor,Myocarditis is a known complication of vaccines for COVID-19,particularly mRNA vaccines.While it is rare,the exact incidence of vaccine-associated myocarditis is unknown.Proponents of personal choice in vaccination decisions often cite the risk of myocarditis as a reason one might choose not to receive the COVID-19 vaccination.Herein,we describe a case of focal myocarditis associated with the Pfizer-BioNTech COVID-19 vaccine and review the literature on the incidence and risk of COVID-19 vaccine-associated myocarditis.
文摘欧洲药品管理局(EMA)近期发布上市许可持有人(Pfizer Europe MA EEIG)就克唑替尼(crizotinib,商品名:赛可瑞/XALKORI)儿童用药患者视觉异常风险的致医生函(DHPC),警示克唑替尼可造成严重的视觉丧失,儿童患者使用克唑替尼需监测视觉情况。主要内容如下:概要视觉异常是克唑替尼的已知风险。在克唑替尼临床试验中。
文摘Background:Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment,we studied mixed priming schedules incorporating an adenoviral-vectored vaccine(ChAdOx1 nCoV-19[ChAd],AstraZeneca),two mRNA vaccines(BNT162b2[BNT],Pfizer-BioNTech,and mRNA-1273[m1273],Moderna)and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant(NVX-CoV2373[NVX],Novavax).
文摘Background:The emergence of the B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine(Pfizer-BioNTech)led to a resurgence of coronavirus disease 2019(Covid-19)cases in populations that had been vaccinated early.On July 30,2021,the Israeli Ministry of Health approved the use of a third dose of BNT162b2(booster)to cope with this resurgence.Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed.Methods:We obtained data for all members of Clalit Health Services who were 50 years of age or older at the start of the study and had received two doses of BNT162b2 at least 5 months earlier.The mortality due to Covid-19 among participants who received the booster during the study period(booster group)was compared with that among participants who did not receive the booster(nonbooster group).A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association of booster status with death due to Covid-19,with adjustment for sociodemographic factors and coexisting conditions.
